Michael Grosso

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

Gary E. Raskob, Nick van Es, Peter Verhamme et al. · New England Journal of Medicine · 2017 · 1.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts.

Janet M. Brown, Michael Grosso, Lance S. Terada et al. · Proceedings of the National Academy of Sciences · 1989 · 266 citations · Full text

Medicine, Cardiology, Pharmacology +13

Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate

Hamim Zahir, Karen Brown, Alexander G. Vandell et al. · Circulation · 2014 · 250 citations

Medicine, Pharmacology, Pharmacotherapy +17

Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial

Andreas Goette, José Luís Merino, Michael D. Ezekowitz et al. · The Lancet · 2016 · 246 citations

Medicine, Cardiology, Pharmacotherapy +12

Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study

Noémie Kraaijpoel, Marcello Di Nisio, Frits I. Mulder et al. · Thrombosis and Haemostasis · 2018 · 214 citations · Full text

Medicine, Hematology, Oncology +17